500
Unit V Promoting Health in Patients With Oxygenation Disorders
Table 24.11 Medications Used in the Treatment of Tuberculosis—cont'd
Medication Classification
Mechanism of Action Inhibits bacterial synthesis of coen- zyme A
Exemplars
Nursing Implications
Pyrazinamide (Rifater, Tebrazid)
Baseline and ongoing laboratory monitoring: l CBC l Chemistries l Renal function l Liver panel l Hepatitis panel l Coagulation
l Uric acid Monitor for: l Signs and symptoms of toxicity (RUQ tenderness, jaundice, fever, abnormal bleeding) l Loss of glycemic control in diabetic patients. Patient education: l Complete the entire course of prescribed medication. l Report onset of dysuria or skin manifestations (acne, rash). l Do not become pregnant or breastfeed during course of therapy. Baseline and ongoing laboratory monitoring: l CBC l Chemistries l Renal function l Liver panel l Hepatitis panel l Coagulation l Uric acid levels Baseline and monthly ophthalmology examination. Monitor for: l Development of visual disturbances—drug can cause optic neuritis that may potentially progress to irreversible blindness. l Onset of urinary symptoms (dysuria, oliguria) Patient education: l Complete the entire course of prescribed medication. l Report any visual changes promptly. l Do not become pregnant or breastfeed during course of therapy.
Ethambutol (Etibi, Myambutol)
Inhibits RNA syn- thesis arresting proliferation of tubercle bacilli
Powered by FlippingBook